The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry

被引:2
|
作者
Braune, Stefan [1 ]
Bluemich, Sandra [2 ]
Bruns, Carola [2 ]
Dirks, Petra [3 ]
Hoffmann, Jeanette [2 ]
Heer, Yanic [4 ]
Rouzic, Erwan Muros-Le [3 ]
Bergmann, Arnfin [1 ]
机构
[1] NeuroTransData, Neuburg An Der Donau, Germany
[2] Roche Pharm AG, Grenzach Wyhlen, Germany
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] PricewaterhouseCoopers PwC, Zurich, Switzerland
关键词
Primary progressive multiple sclerosis; Natural history; Retrospective study; Cohort studies; Quality of life; BURDEN; ONSET; MS;
D O I
10.1186/s12883-023-03273-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundPrimary progressive multiple sclerosis (PPMS) is characterised by gradual worsening of disability from symptom onset. Knowledge about the natural course of PPMS remains limited.MethodsPPMS patients from the German NeuroTransData (NTD) MS registry with data from 56 outpatient practices were employed for retrospective cross-sectional and longitudinal analyses. The cross-sectional analysis included a contemporary PPMS cohort with a documented visit within the last 2 years before index date (1 Jan 2021). The longitudinal analysis included a disease modifying therapy (DMT)-naive population and focused on the evolution of expanded disability status scale (EDSS) from the first available assessment at or after diagnosis within the NTD registry to index date. Outcome measures were estimated median time from first EDSS assessment to first 24-week confirmed EDSS & GE; 4 and & GE; 7. Besides EDSS change, the proportion of patients on disability pension were described over time.ResultsThe cross-sectional analysis included 481 PPMS patients (59.9% female, mean [standard deviation, SD] age 60.5 [11.5] years, mean [SD] EDSS 4.9 [2.1]). Estimated median time from first EDSS assessment after diagnosis to reach 24-week confirmed EDSS & GE; 4 for DMT-naive patients was 6.9 years. Median time to EDSS & GE; 7 was 9.7 years for 25% of the population. Over a decade mean (SD) EDSS scores increased from 4.6 (2.1) to 5.7 (2.0); the proportion of patients on disability pension increased from 18.9% to 33.3%.ConclusionsThis study provides first insights into the German NTD real-world cohort of PPMS patients. Findings confirm the steadily deteriorating course of PPMS accompanied by increasingly limited quality of life.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Primary progressive multiple sclerosis
    Montalban, X
    CURRENT OPINION IN NEUROLOGY, 2005, 18 (03) : 261 - 266
  • [32] Primary progressive multiple sclerosis
    Montalban, X
    Rio, J
    NEUROLOGICAL SCIENCES, 2001, 22 (Suppl 2) : S41 - S48
  • [33] Primary progressive multiple sclerosis
    Brieva, L
    Río, J
    Montalbán, X
    REVISTA DE NEUROLOGIA, 2002, 35 (11) : 1074 - 1080
  • [34] Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?
    Rudick, R
    MULTIPLE SCLEROSIS, 2003, 9 (02): : 210 - 212
  • [35] Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry
    Blaschke, Stefan J.
    Ellenberger, David
    Flachenecker, Peter
    Hellwig, Kerstin
    Paul, Friedemann
    Poehlau, Dieter
    Kleinschnitz, Christoph
    Rommer, Paulus S.
    Rueger, Maria A.
    Zettl, Uwe K.
    Stahmann, Alexander
    Warnke, Clemens
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (06) : 865 - 871
  • [36] Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
    Miller, David H.
    Lublin, Fred D.
    Sormani, Maria Pia
    Kappos, Ludwig
    Yaldizli, Ozgur
    Freedman, Mark S.
    Cree, Bruce A. C.
    Weiner, Howard L.
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Montalban, Xavier
    Uitdehaag, Bernard M. J.
    MacManus, David G.
    Yousry, Tarek A.
    Wheeler-Kingshott, Claudia A. M. Gandini
    Li, Bingbing
    Putzki, Norman
    Merschhemke, Martin
    Haring, Dieter A.
    Wolinsky, Jerry S.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2018, 5 (03): : 346 - 356
  • [37] Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
    Butzkueven, Helmut
    Spelman, Tim
    Horakova, Dana
    Hughes, Stella
    Solaro, Claudio
    Izquierdo, Guillermo
    Kubala Havrdova, Eva
    Grand'Maison, Francois
    Prat, Alexandre
    Girard, Marc
    Hupperts, Raymond
    Onofrj, Marco
    Lugaresi, Alessandra
    Taylor, Bruce
    Giovannoni, Gavin
    Kappos, Ludwig
    Hauser, Stephen L.
    Montalban, Xavier
    Craveiro, Licinio
    Freitas, Rita
    Model, Fabian
    Overell, James
    Muros-Le Rouzic, Erwan
    Sauter, Annette
    Wang, Qing
    Wormser, David
    Wolinsky, Jerry S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1082 - 1090
  • [38] Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
    Braune, Stefan
    Rossnagel, Fabian
    Dikow, Heidi
    Bergmann, Arnfin
    BMJ OPEN, 2021, 11 (08):
  • [39] Relapsing and progressive forms of multiple sclerosis: insights from pathology
    Dutta, Ranjan
    Trapp, Bruce D.
    CURRENT OPINION IN NEUROLOGY, 2014, 27 (03) : 271 - 278
  • [40] The natural history of multiple sclerosis: a geographically based study - 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis
    Cottrell, DA
    Kremenchutzky, M
    Rice, GPA
    Hader, W
    Baskerville, J
    Ebers, GC
    BRAIN, 1999, 122 : 641 - 647